Meet our Speakers
Jacqueline Stevens
Jacqueline Stevens, MD, PhD, MPH recently completed her training in Mohs Micrographic Surgery and Cutaneous Oncology at Brigham and Women's Hospital and Dana-Farber Cancer Institute. She completed her MD and PhD at the University of Virginia School of Medicine and her MPH at the Harvard T.H. Chan School of Public Health. Her clinical interests are focused on high risk skin cancer, including risk stratification and outcomes in high-risk disease. She will be sharing her perspective as a fellow and reflecting on what it means to care for patients with non-melanoma skin cancer during training, and how much patients themselves shape the physicians we become. Outside of medicine, Jacqueline enjoys hiking and skiing, and spending time with her husband Clark, her dog Lilly, and her family.
Nina Ran
Nina Ran is a Mohs surgeon at Brigham and Women’s Hospital and a member of the multidisciplinary Center for Cutaneous Oncology at Dana-Farber Cancer Insitute. Her clinical work and research focus on non-melanoma skin cancer, in particular high-risk squamous cell carcinoma.
David R Carr
David R. Carr, MD MPH is a Professor of Dermatology at The Ohio State University Medical Center. He specializes in Mohs micrographic surgery, cutaneous oncology, and transplant dermatology. He is the Program Director of the Micrographic Surgery and Dermatologic Oncology Fellowship, and serves as the Vice Chair of Academic Affairs within the Department of Dermatology. Dr. Carr’s research interests primarily concentrate on cutaneous oncology and outcomes-based research, particularly in cutaneous squamous cell carcinoma.
Andrea Rustad
Dr. Andrea Rustad is a PGY4 dermatology resident at the University of Wisconsin, who is planning to pursue fellowship in pediatric dermatology after graduating in 2027. She has been involved in many research projects in pediatric dermatology, as well as having written children's books on genetic skin conditions including Gorlin Syndrome, ichthyosis, and epidermolysis bullosa. These books help kids and families feel seen and raise awareness for their conditions, while showing that they are not defined by their skin condition. Dr. Rustad has a specific interest in narrative medicine and the psychosocial impact of dermatologic conditions. Outside of dermatology, she is a dancer and choreographer and performs with the UW Optima dance group, as well as sharing her residency journey and advocating for rare skin diseases on Instagram as @thebalancedderm.
Sean Christensen
Sean R. Christensen, MD, PhD, is Associate Professor of Dermatology and Surgery at Yale University School of Medicine and a fellow of the American College of Mohs Surgery and the American Academy of Dermatology. He is the Program Director for the Yale Micrographic Surgery/Dermatologic Oncology fellowship, Director of Resident Education in Dermatologic Surgery, and Site Director of Yale Dermatologic Surgery-Branford. His referral-based clinical practice is focused on the management of skin cancer, including Mohs surgery, treatment of early stage melanoma, and surgical reconstruction. In addition, Dr. Christensen focuses on complex skin cancer issues such as field cancerization, preventive strategies in high risk patients, and management of advanced or aggressive skin cancer. Dr. Christensen has published extensively on skin cancer pathogenesis and treatment and has experience in clinical trials for basal cell carcinoma. He is a frequent lecturer at national meetings for organizations such as the American Academy of Dermatology and the American College of Mohs Surgery, and currently serves as the Vice President for the International Transplant Skin Cancer Collaborative.
Ryan Sullivan
Dr. Ryan Sullivan is an Associate Professor of Medicine at Harvard Medical School and the Director of Cutaneous Medical Oncology Program and a member of the Termeer Center for Targeted Therapy at Mass General Brigham Cancer Institute. Dr. Sullivan is an active clinical and translational investigator whose main areas of interest are the development of novel molecular targeted and immunotherapeutic combinations for malignant melanoma non-melanoma skin cancer, and other solid tumors. He also has a history of biomarker development in melanoma, including circulating assays measuring proteomic, genomic (e.g. ctDNA) and cellular (e.g. circulating tumor cells), and has been interested in describing, predicting, and optimally treating immune related adverse events from immune checkpoint inhibition. He also serves on multiple committees including serving on the Board of Directors for the Society of Immunotherapy for Cancer (SITC) and the chair of the SITC Immunotherapy Resistance Committee.
Brooke Eggenberger
Brooke Eggenberger, RN, MN, MPH is a clinical research nurse in the Cutaneous Oncology department at Dana-Farber Cancer Institute. She collaborates with physicians to guide and closely monitor patients as they participate in clinical research trials aimed at treating various forms of non-melanoma skin cancer.
Justine Cohen
Justine V. Cohen is a medical oncologist and Senior Physician at Dana-Farber Cancer Institute as well as an Assistant Professor of Medicine at Harvard Medical School. She is a clinical and translational investigator specializing in the treatment of patients with cutaneous malignancies including malignant melanoma, squamous cell carcinoma, Merkel cell carcinoma and other rare cutaneous malignancies. Additionally, she serves as the lead physician for cutaneous malignancies in the Center for Cancer Therapeutic Innovation (Early Drug Development Program). She completed a mid-career fellowship in Hospice and Palliative Medicine in 2023. Her experience as a clinical and translational investigator includes developing and enrolling patients on clinical trials with the goal of finding novel approaches to treat melanoma and non-melanoma skin cancers while minimizing toxicity and maximizing quality of life. Dr. Cohen’s background combines clinical research, patient care, and humanities in medicine.
Ann Silk
Dr. Silk is a medical oncologist specializing in advanced skin cancers at Dana-Farber Cancer Institute and on faculty at Harvard Medical School. Dr. Silk received MD and MS in Clinical Research from the University of Pittsburgh School of Medicine in 2008. She completed her Hematology/Oncology fellowship at the University of Michigan in 2014. She cares for patients with Merkel cell carcinoma, cutaneous squamous cell carcinoma, melanoma, and rare skin cancers such as extramammary Paget’s disease, primary cutaneous adenocarcinoma, sweat gland carcinoma and sebaceous cell carcinoma. Dr. Silk is the Co-Director of the Merkel Cell Carcinoma Center of Excellence and the Director of Cutaneous Oncology Clinical Research. Dr. Silk served on the Board of Directors for the Society for Immunotherapy of Cancer (SITC) and led the development of the SITC Clinical Practice Guideline on Nonmelanoma skin cancers.
Arianna Maida
I am a medical oncology PA at DFCI in the cutaneous oncology department. I started at DFCI in 2020 as an inpatient oncology PA. I transitioned to outpatient oncology with cutaneous in 2023 and still work per diem with inpatient oncology. Outside of work, I am a long-distance runner.
Anokhi Jambusaria
"Dr. Anokhi Jambusaria is an associate professor and Section Chief of Dermatology, at the Department of Internal Medicine at Dell Medical School in Austin, TX. She earned her medical degree from the Temple University School of Medicine and completed both her dermatology residency and master’s degree in epidemiology (MSCE) from the University of Pennsylvania School of Medicine. Upon her graduation, she worked at Mayo Clinic Jacksonville, specializing in transplant dermatology and high-risk skin cancer, before relocating to Texas in 2015. As an epidemiologist, Dr. Jambusaria has a strong research interest in high-risk skin cancer and transplant dermatology. Early in her career, she was the recipient of the prestigious Dermatology Foundation Career Development Award in Public Policy. The results of her research in squamous cell carcinoma outcomes were incorporated in the 8th edition American Joint Committee on Cancer staging for cutaneous SCC. Dr. Jambusaria’s research interests also include defining and optimizing care for patients with field cancerization and skin cancer prevention, particularly in the immunosuppressed population. She previously served as President of the International Transplant Skin Cancer Collaborative (ITSCC) and currently is on the board of the Skin Cancer Outcomes Consortium (SCOUT).
Support for this program is provided by:
